Skip to main content

Teresa Kathleen Tarrant

Associate Professor of Medicine
Medicine, Rheumatology and Immunology
200 Trent Dr., DUMC 3874, Durham, NC 27710
235 Sands Resarch Bldg, 303 Research Dr., Durham, NC 27710

Overview


I first became interested in clinical immunology as a medical student studying autoimmune inflammatory eye disease at the National Institutes of Health.  Since then, I have been inspired to understand what causes autoimmunity and immune deficiency disorders in order to improve the quality of life for my patients.  I see patients with multiple complex immune disorders with particular expertise in autoimmune and Rheumatoid arthritis, primary Sjogren's syndrome, and the immunodeficiency disorders Common Variable Immunodeficiency (CVID), Adenosine Deaminase Deficiency (ADA) disorders, and WHIM (Warts, Hypogammaglobulinemia, Infections, and Myelokathexis). My research investigates immune targets that may impact either the development of immune disease or identify new therapies for patients.  The goal is to help us understand why and how immunologic diseases develop so that we may better treat them.

Current Appointments & Affiliations


Associate Professor of Medicine · 2018 - Present Medicine, Rheumatology and Immunology, Medicine

In the News


Published November 30, 2022
After a Tough Summer, X4 Celebrates Phase III Win in WHIM Syndrome
Published December 8, 2020
Three I&E Incubation Awards Fund Novel Ideas to Solar Energy, IBD & Medical Laser Research
Published July 14, 2020
Accuracy in Rheumatoid Arthritis Testing Can Improve Diagnosis, Lower Costs

View All News

Recent Publications


Clinicopathologic Features and the Spectrum of Myelokathexis in Warts, Hypogammaglobulinemia, Infections, Myelokathexis Syndrome.

Journal Article Lab Invest · April 14, 2025 Warts, hypogammaglobulinemia, infections, myelokathexis (WHIM) syndrome is a rare primary immunodeficiency disorder predominantly caused by germline CXCR4 variants. Bone marrow (BM) evaluation showing myelokathexis helps to establish the diagnosis of WHIM ... Full text Link to item Cite

Multi-Year Registry Study of Elapegademase Treatment in Patients With Adenosine Deaminase Severe Combined Immunodeficiency (ADA-SCID) Requiring Enzyme Replacement Therapy.

Journal Article J Clin Immunol · March 27, 2025 PURPOSE: The safety and tolerability of elapegademase (elapegademase-lvlr; Revcovi®) a PEGylated recombinant adenosine deaminase (ADA), were demonstrated in two Phase 3 clinical trials in the U.S. and Japan in patients with ADA-deficient severe combined im ... Full text Link to item Cite
View All Publications

Education, Training & Certifications


University of Florida, College of Medicine · 1999 M.D.